OR AKIVA, Israel & WEST HILLS, Calif.--(BUSINESS WIRE)--Medical Compression Systems, Ltd. (TASE: MDCL), a company specializing in innovative non-invasive blood circulation solutions, today announced publication of the results from the landmark head-to-head S.A.F.E. (S.F.T. Alternative to Enoxaparin) study. The results, published as the lead article in the March 2010 issue of Journal of Bone and Joint Surgery, demonstrated that the ActiveCare+S.F.T® non-invasive mobile compression system, used as monotherapy, achieved no significant difference in efficacy and a significant decrease in major bleeding events compared to Lovenox® (enoxaparin sodium injection) in the prevention of venous thromboembolism (VTE) in total hip arthroplasty (THA).
